BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CTMSS - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CTMSS
X-ORIGINAL-URL:https://clinicaltmssociety.org
X-WR-CALDESC:Events for CTMSS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20241001T080000
DTEND;TZID=UTC:20241001T170000
DTSTAMP:20260404T093006
CREATED:20241016T154318Z
LAST-MODIFIED:20241017T010310Z
UID:1120-1727769600-1727802000@clinicaltmssociety.org
SUMMARY:Apples and Oranges: Comparative Effectiveness Research in TMS
DESCRIPTION:> > Register Now <<\nAlthough not labeled as such by the FDA\, TMS is considered a third line treatment by many practitioners and health insurance company policies. Earlier referral to TMS is not commonly practiced but may be non-inferior to or superior to medication switches or augmentation. Our field lacked trials that compared different modalities of treatment in parallel with TMS until recently\, which is the subject of this webinar. \nThe core aspect of this webinar will be reviewing two very recent articles that compare TMS to antidepressant medications. We will also review basic concepts of non-inferiority trials and meta-analyses. \nAt the end of the presentation\, attendees will be able to: \n\nUnderstand "head-to-head" trials and meta-analyses research.\nReview and understand recent comparative articles on TMS.\nReview and understand the current and future placement of TMS in the treatment algorithms of depression.\n\nFormat: On Demand Webinar \nCost: Members: $25 | Non-members $50 | Trainee Members FREE \nSpeaker: Mehmet Dokucu\, D\, PhD\, DFAPA \n \nDr. Dokucu is a broadly trained neuroscientist (PhD) and academic psychiatrist (MD) with expertise in Electroconvulsive Therapy\, Transcranial Magnetic Stimulation\, Consultation Liaison Psychiatry and Psycho-oncology. He was the founding director of the Transcranial Magnetic Stimulation program at Northwestern Medicine in Chicago. He is currently an Associate Professor of Psychiatry at Dartmouth Geisel School of Medicine and he currently directs the Mood Disorders and Interventional Psychiatry Program at Dartmouth Hitchcock Medical Center. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/apples-and-oranges-comparative-effectiveness-research-in-tms-2/
LOCATION:Zoom
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/October_intro_slides.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240910
DTEND;VALUE=DATE:20240911
DTSTAMP:20260404T093006
CREATED:20241108T132217Z
LAST-MODIFIED:20241108T134039Z
UID:1560-1725926400-1726012799@clinicaltmssociety.org
SUMMARY:September 10\, 2024 Town Hall Member Meeting
DESCRIPTION:Join the Clinical TMS Society President Martha Koo\, MD\, FAPA\, FASAM\, FCTMSS\, committee co-chairs\, and other Society volunteers for an update on current activities.\nThis is your opportunity to learn more about the Society's various goals and projects.\n>>MEMBER WATCH NOW<<
URL:https://clinicaltmssociety.org/event/september-10-2024-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/logoongray_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240903T080000
DTEND;TZID=UTC:20240903T090000
DTSTAMP:20260404T093006
CREATED:20241017T010219Z
LAST-MODIFIED:20241017T010328Z
UID:1177-1725350400-1725354000@clinicaltmssociety.org
SUMMARY:Stimulating for Hope: Transcranial Magnetic Stimulation for Patients at Risk for Suicide
DESCRIPTION:> > Register Now <<\n\nThe United States is in the midst of a crisis of suicide\, and TMS providers often must confront this directly. In this presentation\, Dr. Philip will provide a brief overview of the existing TMS protocols used to reduce suicidal ideation\, reviewing their efficacy and also burden of administration. He will describe an ongoing clinical trial combining TMS plus psychotherapy for PTSD\, and outline his own clinical approach to treating suicidal patients\, so that attendees can consider how they can address this critically important issue. \nAt the end of the presentation\, attendees will be able to: \n\nDescribe various evidence-based TMS parameters to treating patients at higher suicide risk.\nDemonstrate understanding of the interaction (or lack thereof) between changes in depression and suicidal ideation during TMS.\nDiscuss future TMS options in high risk patients.\n\nFormat: On-Demand Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: Noah S. Philip\, MD \n \nDr. Philip is a Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the founding Section Chief of Psychiatric Neuromodulation at VA Providence\, and is Lead for Mental Health Research at the VA RR&D Center for Neurorestoration and Neurotechnology. \nDr. Philip received his BSc from McGill University and his MD from Albany Medical College where he graduated AOA and with a Distinction in the Study of Biomedical Ethics. He completed his psychiatry residency training at Brown University\, followed by T32 and Neuromodulation Fellowships at Brown. \nDr. Philip’s laboratory uses a precision approach to new and emerging technologies\, with the goal to understand and treat posttraumatic stress disorder\, major depression\, and suicidality. His research has been featured in JAMA Psychiatry\, American Journal of Psychiatry\, Biological Psychiatry\, and the National Neuroscience Curriculum Initiative (tDCS+Virtual Reality for PTSD). He is currently conducting an NIMH-funded cooperative study to perform a first-in-human study investigating MRI-guided low intensity focused ultrasound for depression and anxiety (U01 MH123427). \nDr. Philip has received awards and recognition from the American Psychiatric Association\, Society for Biological Psychiatry\, American College of Neuropsychopharmacology\, and others. He has been funded through grants from the VA (Rehabilitation\, Clinical Science\, and Health Services R&D)\, NIMH\, NIDA\, Department of Defense\, and through industry and small-business collaborations. He is active in several national organizations\, including SOBP and ACNP\, and is a past President of the Psychiatric Research Society. \nDr. Philip plays a significant training and mentoring role at Brown\, where he is Associate Director of the NIMH R25 psychiatry resident research training program\, and serves as a mentor through national organizations such as the Career Development Institute for Psychiatry. He is committed to action to improve diversity\, equity\, inclusion\, and belonging. \n\n> > Register Now <<
URL:https://clinicaltmssociety.org/event/stimulating-for-hope-transcranial-magnetic-stimulation-for-patients-at-risk-for-suicide/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/September_intro_slides-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240806T200000
DTEND;TZID=UTC:20240806T210000
DTSTAMP:20260404T093006
CREATED:20240731T205123Z
LAST-MODIFIED:20241017T010542Z
UID:405-1722974400-1722978000@clinicaltmssociety.org
SUMMARY:What Does a TMS Doctor Need to Know About Brain Networks?
DESCRIPTION:> > Register Now <<\nNetwork neuroscience is becoming increasingly relevant to the clinical practice of TMS\, but it is a large and complicated field that is impossible for a clinician to follow comprehensively. This lecture will provide a basic foundation of brain networks and describe general principles for how to recognize when a new development in this field is clinically useful. \nAt the end of this presentation participants will: \n\nDefine specific brain networks currently involved in TMS targeting.\nAppraise new network-based TMS targets to determine when they are ready for clinical practice.\nRecognize which brain network studies are not clinically useful yet.\n\nOne Hour CME Credit Available \nFormat: On-Demand Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: Shan H. Siddiqi\, MD \n \nDr. Siddiqi is an assistant professor of psychiatry at Harvard Medical School\, a neuropsychiatrist at Brigham & Women’s Hospital\, and director of psychiatric neuromodulation research for the Center for Brain Circuit Therapeutics. His research is focused on causal mapping of human brain function and dysfunction. Using techniques such as functional MRI\, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as TMS to alleviate symptoms in psychiatric disorders. His work has been recognized with multiple awards from the National Institute of Mental Health\, the Brain & Behavior Research Foundation\, the American Neuropsychiatric Association\, the American College of Neuropsychopharmacology\, Harvard Medical School\, and many others. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/how-to-understand-the-exploding-evidence-on-new-circuit-based-tms-targets/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/August_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240702T200000
DTEND;TZID=UTC:20240702T210000
DTSTAMP:20260404T093006
CREATED:20241022T125801Z
LAST-MODIFIED:20241022T125801Z
UID:1298-1719950400-1719954000@clinicaltmssociety.org
SUMMARY:What’s the Secret Recipe? Treating Depression with TMS in the Era of Accelerated Protocols and Functional MRI Targeting
DESCRIPTION:Methods for enhancing the antidepressant effects and treatment efficiency of transcranial magnetic stimulation have advanced rapidly in the past several years\, with new FDA-cleared protocols and promising early data. Dr. Trapp will discuss the evidence for various TMS optimization procedures with a focus on trying to understand the “secret recipe” for delivery of the most efficacious TMS treatment protocol. \nDuring this presentation participants will: \n\nDiscuss current methods and considerations for TMS targeting of the DLPFC for depression treatment.\nDiscuss current evidence for dose-response effects and accelerated TMS protocols for depression.\nReview methods and data for optimizing the antidepressant effects of TMS.\n\nOne Hour CME Credit Available \nFormat: Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: Nicholas T. Trapp\, MD \n \nDr. Trapp is an Assistant Professor of Psychiatry at the University of Iowa\, where he is the Director of the Interventional Psychiatry Program and the Neuropsychiatry Clinic.  He completed psychiatry residency at Washington University in St. Louis\, followed by post-doctoral fellowship in neurostimulation and neuroimaging at the University of Iowa and behavioral neurology/neuropsychiatry at Stanford University. His research focuses on the targeting\, application\, and optimization of neuromodulation therapies for the treatment of psychiatric conditions. Projects have included novel TMS clinical trials\, mechanistic TMS studies\, and lesion-network mapping of psychiatric symptoms to identify candidate brain stimulation targets. He also leads the TMS for Depression Consensus Recommendations Work Group as part of the National Network of Depression Centers Neuromodulation Task Group and serves on the Clinical TMS Society Research Committee. Clinically Dr. Trapp evaluates patients for TMS\, ECT\, DBS\, VNS\, and esketamine.  He has received Career Development Awards from the National Institutes of Mental Health and the American Neuropsychiatric Association\, as well as a Young Investigator Award from the Brain and Behavior Research Foundation. His current research funding is to study the electrophysiologic effects of TMS in epilepsy patients with intracranial recording electrodes.
URL:https://clinicaltmssociety.org/event/whats-the-secret-recipe-treating-depression-with-tms-in-the-era-of-accelerated-protocols-and-functional-mri-targeting/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/July_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240507T170000
DTEND;TZID=UTC:20240507T180000
DTSTAMP:20260404T093006
CREATED:20240729T045056Z
LAST-MODIFIED:20241017T011001Z
UID:295-1715101200-1715104800@clinicaltmssociety.org
SUMMARY:The Unique Case of Bipolar Depression and Transcranial Magnetic Stimulation
DESCRIPTION:> > Register Now <<\nThere are few level 1 evidence based treatments for bipolar depression\, and when these are either ineffective or poorly tolerated alternative non-pharmacological treatments are required. Non-invasive neurostimulation\, in particular transcranial magnetic stimulation\, is a treatment option for difficult to treat depression that is of interest in bipolar depression. In 2020\, the FDA granted breakthrough designation for TMS for bipolar depression\, however if it does receive approval it remains to be determined where TMS belongs in the bipolar depression algorithm. Here\, we will review the management of bipolar depression\, and review the peer reviewed literature using TMS to treat bipolar depression. In particular\, the conflicting data will be contextualized within the unique biological and pharmacological constraints that characterize bipolar disorder. \nAt the end of this presentation participants will: \n\nUnderstand the current management of bipolar depression.\nReview the clinical trial and open label literature using TMS to treat bipolar depression.\nAppreciate the complex interplay between biology and pharmacology that makes TMS in bipolar disorder unique.\n\n1 CME Credit Available \nFormat: Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSpeaker: Alexander McGirr\, MD\, PhD\, FRCPC \nAlexander McGirr received his MSc in neuroscience at McGill University under Dr. Gustavo Turecki before pursuing medical school at the University of Toronto. There\, in addition to medical studies he pursued basic science training under Dr. John Roder. His research track psychiatry residency at the University of British Columbia\, where his clinical research in mood disorders was under Drs. Lam and Yatham\, included a contemporaneous PhD in Neuroscience under Dr. Timothy Murphy. His independent research includes two fronts: 1) a human research program that is both pre-clinical and clinical using non-invasive brain stimulation to probe and treat neuropsychiatric illness\, and 2) a basic science program using animal models and next gen technologies for circuit dissection and to understand how risk factors related to neuropsychiatric illness change neural circuitry in an effort to inform treatments in humans. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/the-unique-case-of-bipolar-depression-and-transcranial-magnetic-stimulation/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/May.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240402T080000
DTEND;TZID=UTC:20240402T210000
DTSTAMP:20260404T093006
CREATED:20241017T011237Z
LAST-MODIFIED:20241021T200002Z
UID:1184-1712044800-1712091600@clinicaltmssociety.org
SUMMARY:Electroconvulsive Therapy: How to Make a Highly Effective Treatment More Acceptable
DESCRIPTION:> > Register Now <<\nElectroconvulsive therapy (ECT) is a highly effective treatment for major depression.  However\, it is underused due to stigma and concern over its side effects on memory.  This webinar will describe the history of ECT including its many improvements over more than 80 years. This will be followed by a presentation of recent research that aims to make ECT more acceptable by minimizing its side effects on memory through better understanding of the mechanisms of its therapeutic effect on depression and its adverse effects on memory. \nAt the end of this presentation participants will: \n\nBe familiar with the history of ECT including its improvements over more than 80 years.\nBe aware of the therapeutic effect of ECT on major depression and the adverse effect of ECT on memory.\nLearn of new research into the mechanisms of the therapeutic and adverse effects of ECT that aims to make ECT more acceptable by minimizing its side effects on memory.\n\n1 Hour CME Credit Available \nFormat: Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \nSpeaker: William T. Regenold\, MDCM \n \nWilliam T. Regenold\, MDCM is a board certified general and geriatric psychiatrist.  He is a Senior Research Physician and the Medical Director of the Noninvasive Neuromodulation Unit (NNU) in the Experimental Therapeutics and Pathophysiology Branch of the National Institute of Mental Health (NIMH).  At the NIMH\, he collaborates with a research team investigating electroconvulsive therapy and transcranial magnetic stimulation\, primarily in the treatment of major depression. Dr. Regenold studied medicine at McGill University in Montreal.  He trained in Medicine\, Neurology and Psychiatry at the Johns Hopkins Bayview Medical Center in Baltimore and in Psychiatry and Old Age Psychiatry at the Johns Hopkins Hospital in Baltimore and the Maudsley Hospital in London. Prior to joining the NIMH\, he was at the University of Maryland Department of Psychiatry where he was Director of the Division of Geriatric Psychiatry\, the Adult Inpatient Service\, and the Electroconvulsive Therapy Service.  His research at the University of Maryland focused on mood disorder pathophysiology and electroconvulsive therapy. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/electroconvulsive-therapy-how-to-make-a-highly-effective-treatment-more-acceptable/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/April_Grand_Rounds.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240305T080000
DTEND;TZID=UTC:20240305T210000
DTSTAMP:20260404T093006
CREATED:20241017T011402Z
LAST-MODIFIED:20241021T200245Z
UID:1189-1709625600-1709672400@clinicaltmssociety.org
SUMMARY:Research and Clinical Applications of TMS in Pediatric and Neurodevelopmental Populations
DESCRIPTION:> > Register Now <<\nThe CDC currently estimates that nearly 1 in 5 children have a developmental or psychiatric disorder; yet evidence-based\, targeted treatments for these disorders are lacking. \nTaking an Experimental Therapeutics approach\, the research that will be discussed aims to understand the mechanisms that contribute to dysfunctional development of neural systems associated with symptoms of pediatric psychiatric and neurodevelopmental disorders utilizing neuroimaging and neurophysiological tools combined with transcranial magnetic stimulation interventions. The ultimate goal of the research that will be discussed is to inform the development of novel targeted device-based treatment strategies. Though there is much promise for these targeted device-based interventions\, data on the safety and efficacy of these interventions in pediatric and neurodevelopmental populations is limited. The current state of the research will be reviewed and future directions for the field will be discussed. \nAt the end of this presentation participants will be able to: \n\nReview the findings of studies using TMS to probe physiology in autism spectrum disorder (ASD).\nDescribe how TMS can be used to induce long-term changes in brain network functioning and potentially treat pediatric neuropsychiatric and behavioral disorders.\nIdentify potential network targets where applying TMS may be effective for reducing transdiagnostic symptom domains commonly seen in neuropsychiatric and behavioral disorders.\n\n1 Hour CME Credit Available \nFormat: Live Webinar \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSpeaker: Lindsay Oberman\, PhD \n \nDr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time\, she has published over 60 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism\, mood disorders\, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation\, sensory processing\, social cognition\, and executive functioning across disorders. In doing so\, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/research-and-clinical-applications-of-tms-in-pediatric-and-neurodevelopmental-populations-2/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/March_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20240206T190000
DTEND;TZID=America/Chicago:20240206T200000
DTSTAMP:20260404T093006
CREATED:20240730T004806Z
LAST-MODIFIED:20241017T011442Z
UID:318-1707246000-1707249600@clinicaltmssociety.org
SUMMARY:Controlling Brain State Variability to Optimize rTMS Efficacy
DESCRIPTION:> > Register Now <<\nThe Clinical TMS Society presents this installment of our Grand Rounds Webinar Series: Controlling Brain State Variability to Optimize rTMS Efficacy featuring Speaker: Lysianne Beynel\, PhD \nIn this presentation\, we will explore the pivotal role of brain state variability in influencing basic TMS outcomes like MEP and phosphenes. We will then focus on some clinical applications that used control of state-dependency as a proof of principle. Finally\, in a demonstration of a specific case of state-dependency control\, we will uncover the potential synergy between rTMS and cognitive therapy in\nimproving depression treatment\, as a way to pave the way for more personalized and effective therapies. \nAt the end of this presentation participants will be able to:\n• Demonstrate how varying brain states affect basic TMS measures like motor\nevoked potentials (MEPs) and phosphenes.\n• Evaluate the impact of controlling brain state on improving rTMS outcomes as\na proof of principle.\n• Examine the potential benefits of combining rTMS with cognitive therapy for\ntreating depression in this context. \nTake advantage of our live Q&A session at the conclusion of the webinar! \n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\n \nSpeaker: Lysianne Beynel\, PhD \nDr. Beynel completed her PhD at University Grenoble Alpes in France where she\ninvestigated the effects of transcranial magnetic stimulation (TMS) on bipolar\ndisorders. She then moved to Duke University for her post-doc work\, where she\ninvestigated the use of rTMS in improving working memory in older adults. Her\nresearch\, at that time\, was mainly focused on the effects of ‘online’ TMS\, i.e.\, applying\nstimulation while participants were performing a task\, as a potential means to further\nengage the stimulated network and produce stronger effect. She is now a Research\nFellow at the NonInvasive Neuromodulation Unit (NNU) in the Experimental\nTherapeutics and Pathophysiology Branch of the National Institute of Mental Health\,\nwhere she is combines two of these skill sets to apply TMS during cognitive therapy to\nimprove outcomes in depressive disorders. Dr. Beynel is also exploring the potential\nof combining real-time fMRI neurofeedback with rTMS to achieve more precise control\nover brain state. \n\n> > Register Now <<
URL:https://clinicaltmssociety.org/event/controlling-brain-state-variability-to-optimize-rtms-efficacy/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/February_thumbnail_2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240109T080000
DTEND;TZID=UTC:20240109T210000
DTSTAMP:20260404T093006
CREATED:20240815T015312Z
LAST-MODIFIED:20241021T200438Z
UID:847-1704787200-1704834000@clinicaltmssociety.org
SUMMARY:TMS Documentation: Expert Perspectives
DESCRIPTION:> > Register Now <<\nThe CTMSS Insurance Committee presents: "TMS Documentation: Expert Perspectives". In this panel discussion\, we will discuss the range of approaches when it comes to documenting TMS sessions. We will also explore how the documentation serves multiple purposes for different audiences: clinical and administrative staff\, patients\, payers\, and the court. \nAt the end of this presentation\, participants will be able to: \n\ndescribe the core elements of a TMS procedure note in order to adequately convey clinical information to others involved in the care of a patient.\nunderstand the range of approaches to documentation of TMS sessions and the benefits and limitations of each approach.\ndevelop an approach to documentation of TMS sessions for your practice that meets the expectations of relevant insurance plans and malpractice carriers.\n\nThis Grand Rounds Webinar will highly encourage audience participation! \n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\n  \n\nPanelists:\nSam Huber\, MD\, MS \n \nDr. Huber is an experienced physician executive and clinical psychiatrist. He holds degrees from the University of Rochester\, University of Rochester School of Medicine\, and the Dartmouth Institute for Health Policy and Clinical Practice. He trained at Washington University in St. Louis and the White River Junction Vermont VA Medical Center. He has served as Medical Director for Inpatient Psychiatry\, Medical Director for Interventional Psychiatry\, and Associate Quality Officer at the University of Rochester Medical Center\, Associate CMO for Patient Safety and Quality at Rochester Regional Health (Rochester\, NY)\, and Chief Medical Officer for MultiCare Behavioral Health-MultiCare Health System (Tacoma\, WA). He has clinical experience across the spectrum of acute services including short and long-term inpatient\, emergency psychiatry\, consultation/integrated care\, neuromodulation (ECT\, TMS) and adult ambulatory psychiatry. As Medical Director for Interventional Psychiatry\, Dr. Huber partnered with multiple divisions and stakeholders to sustain a margin-positive ECT service and launch the Rochester region’s first TMS service within a health system. \nShelly Lahn\, MBA \n \nShelly Lahn is the CEO of Neuro Wellness TMS Centers of America where they specialize in transcranial magnetic stimulation (TMS). \n\nCTMSS Insurance Committee member\nNational Ketamine Task Force member\nOwner/Operator/Founder of Neuro Wellness Centers of America using Apollo TMS Machines\n\nRebecca Allen\, MD\, MPH \n \nDr. Allen graduated with a B.A. in Psychology with honors from Stanford University. She attended Oregon Health and Science University for medical school where she also earned a Masters of Public Health in biostatistics and epidemiology. She completed psychiatry residency at the Harvard Longwood Psychiatry Residency Training Program\, a joint program between Brigham and Women’s Hospital\, Beth Israel Deaconess Medical Center\, and Massachusetts Mental Health Center. She served as Chief Resident of the psychiatry consult service at Beth Israel Deaconess Medical Center. She then went on to complete a 2-year fellowship in Neuropsychiatry at Brigham and Women’s Hospital. She has participated in research on sleep and memory consolidation\, quality of life in multiple sclerosis\, efficacy of different TMS protocols\, EEG biomarkers of TMS response\, the RECOVER VNS trial\, and other projects. She has authored several papers. \nModerator:\nCarlene MacMillan\, MD \n \nDr. MacMillan is the Chief Medical officer at Osmind. Osmind is a technology platform that helps clinicians who provide breakthrough mental health treatments track outcomes and document interventions. She is the Co-Chair of the Clinical TMS Society Insurance Committee and on the Board of Directors of the Clinical TMS Society. She participates in neuromodulation clinical trials and post-marketing research. She completed her medical training at Harvard medical school and her adult psychiatry residency and child psychiatry fellowship at Massachusetts General Hospital and McLean Hospital. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/tms-documentation-expert-perspectives/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/08/January_24_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231205T200000
DTEND;TZID=UTC:20231205T210000
DTSTAMP:20260404T093006
CREATED:20240731T212112Z
LAST-MODIFIED:20241017T011909Z
UID:413-1701806400-1701810000@clinicaltmssociety.org
SUMMARY:Precision Organizational and Functional Estimates for TMS Targeting
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Precision Organizational and Functional Estimates for TMS Targeting featuring Dr. Mark Eldaief! \nNetwork models are increasingly invoked to characterize the neurobiological underpinnings of mental illnesses. Dysfunction within specific networks (e.g.\, the default\, salience and control networks) promotes the formation of specific symptoms. This suggests an opportunity to treat specific depressive symptoms by modulating specific circuits with transcranial magnetic stimulation (TMS). In this talk\, I will review our project which uses precision MRI methods to delineate cortical networks in the individual at high resolution and to then stimulate specific networks in separate sessions with TMS. We will then survey the differential impact of network-specific stimulation with REST-BOLD and TASK-BOLD imaging as well as with validated state-based questionnaires and brief neuropsychological tests. This work will facilitate individualized neuromodulation approaches based on network topography. This will pollinate large-scale clinical trials assessing the effects of differential circuit modulation. It will also illuminate circuit-construct relationships across neuropsychiatric disorders. \nAt the end of this presentation participants will be able to: \n\ndescribe the network basis of specific psychopathological symptoms in depression.\nidentify the use of precision MRI to define cortical networks in the individual.\nlist the methods of applying TMS to specific networks in the individual to modulate specific symptom domains.\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nMark Eldaief\, MD\n \nDr. Eldaief attended medical school at Columbia University. Following this\, he did a combined residency in Neurology and Psychiatry at Columbia and a Research Fellowship in Cognitive Neurology at the Beth Israel Deaconess Medical Center. He is now an Assistant Professor of Neurology at Harvard Medical School and is a staff neurologist and psychiatrist at the Massachusetts General Hospital. \n\n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/precision-organizational-and-functional-estimates-for-tms-targeting/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/December_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231107T200000
DTEND;TZID=UTC:20231107T210000
DTSTAMP:20260404T093006
CREATED:20240730T012022Z
LAST-MODIFIED:20241017T011945Z
UID:323-1699387200-1699390800@clinicaltmssociety.org
SUMMARY:Vagus Nerve Stimulation: What Do We Have When All Treatments Have Failed?
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Vagus Nerve Stimulation: What Do We Have When All Treatments Have Failed?  featuring Dr. Scott Aaronson! \nDespite compelling evidence for efficacy\, vagus nerve stimulation has languished due to problems with the design of two randomized clinical trials which led to a non coverage determination (NCD) made by in Centers for Medicare and Medicaid (CMS) in 2007.  After a seminal comparative observational study was published in 2017\, CMS agreed to rescind its NCD and agreed to fund a coverage with evidence  development study for up to 1000 participants with either unipolar or bipolar depression.  The unipolar arm of the one year study will be completed in the Spring of 2024.  In preparation for the potential clinical availability of VNS\, we will review the proposed mechanism of action\, identify appropriate candidates\, review the existing outcomes data and discuss the advantages and disadvantages of this unique albeit invasive treatment approach for the most severely treatment resistant depressions. \nAt the end of this presentation participants will be able to: \n\n describe the proposed mechanism of action for VNS\n identify potential candidates for the use of VNS\n list the most frequent adverse events found in the use of VNS\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nScott T. Aaronson\, MD\, DLLAPA\, FCTMSS\n \nDr. Scott Aaronson is a thought leader in the areas of biological psychiatry\, diagnosis\, and the integration of somatic and psychological therapies. He is an adjunct professor of psychiatry at the University of Maryland School of Medicine\, distinguished life fellow of the American Psychiatric Association\, and is a fellow of the American College of Psychiatrists. Dr. Aaronson also serves/served on the boards of the American Society of Clinical Psychopharmacology and the Clinical TMS Society. \nIn addition to his work at The Retreat\, Dr. Aaronson is the director of clinical research programs at Sheppard Pratt\, where he is the principal investigator for multiple studies on the development of therapies for mood and anxiety disorders. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders\, and has published numerous articles on his research including pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS)—in the treatment of severe refractory mood disorders. Most recently\, he was named the Chief Science Officer of the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics\, focused on the development of uses for psychedelic medications across the spectrum of psychiatric illness. \n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/vagus-nerve-stimulation-what-do-we-have-when-all-treatments-have-failed/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/November_7_GRWS_Event_Thumbnail_V3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20231003T200000
DTEND;TZID=UTC:20231003T210000
DTSTAMP:20260404T093006
CREATED:20240731T204319Z
LAST-MODIFIED:20241017T012013Z
UID:403-1696363200-1696366800@clinicaltmssociety.org
SUMMARY:Neuromodulation for the Traumatized Brain: Modulating Dysfunctional Neural Networks in PTSD
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Neuromodulation for the Traumatized Brain: Modulating Dysfunctional Neural Networks in PTSD  featuring Dr. Sandeep Vaishnavi! In this presentation\, Sandeep Vaishnavi\, MD\, PhD will discuss the neural networks involved in stress and fear responses thought to be dysfunctional in PTSD.  He will review nodes in these networks that could be modulated by TMS.  He will then review the current state of evidence of TMS for PTSD\, including figure-of-8 coil\, H-coil\, and theta burst studies. At the end of this presentation participants will be able to: \n\n describe the neural networks thought to be dysfunctional in PTSD\n explain the strategies used to modulate nodes in these dysfunctional networks\n understand the current state of evidence for use of neuromodulation to improve PTSD symptoms\n\n1 Hour CME Credit available Format: On-Demand Cost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nSandeep Vaishnavi\, MD\, PhD\nDr. Sandeep Vaishnavi is a faculty network member of the Duke Institute for Brain Sciences (DIBS) and an adjunct associate in the Department of Medicine at Duke University.  He is the president of the Center for Neuropsychiatry and Brain Stimulation (CNBS)\, an ARC Health practice.  He is the co-author of the books\, The Traumatized Brain:  A Family Guide to Understanding Mood\, Memory\, and Behavior after Brain Injury and Healing the Traumatized Brain:  Coping after Concussion and other Brain Injuries. \n\n  \n  \n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/neuromodulation-for-the-traumatized-brain-modulating-dysfunctional-neural-networks-in-ptsd/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/October_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230905T180000
DTEND;TZID=UTC:20230905T190000
DTSTAMP:20260404T093006
CREATED:20240731T195314Z
LAST-MODIFIED:20241017T012055Z
UID:393-1693936800-1693940400@clinicaltmssociety.org
SUMMARY:The Great Potential of QPS for Optimizing rTMS Outcomes
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: The Great Potential of QPS for Optimizing rTMS Outcomes featuring Dr. Amanda Tiksnadi! \nTranscranial magnetic stimulation (TMS) has been known as a novel technique to modulate brain neuronal activity non-invasively. The magnitude and direction of modulatory effects of rTMS critically depend on the chosen protocol variables\, e.g. stimulation intensity\, frequency\, train length\, intertrain-interval\, total number of magnetic pulse\, as well as the coil configuration\, current direction\, pulse waveform\, and position of the coil with respect to the cortex. Several methods have been validated to increase the efficacy of rTMS\, i.e.\, iTBS and cTBS. This presentation will cover a new emerging method of QPS (Quadripulse Stimulation) that has shown higher efficacy in motor cortical plasticity than the previous method. This method may solve some of the major obstacles in achieving treatment efficacy for “rTMS-resistant” patients. \nAt the end of this presentation\, participants will be able to: \n\n Describe the basics of Quadripulse Stimulation\n Explain the efficacy of Quadripulse Stimulation on motor cortical plasticity\n Discuss the potential of Quadripulse Stimulation for optimizing rTMS outcomes\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nAmanda Tiksnadi\, MD\, PhD\n \nDr. Amanda Tiksnadi is a neurologist at the Neurology Department\, Faculty of Medicine\, Universitas Indonesia. Her special interests are movement disorders\, neurorestoration & neuroengineering\, and non-invasive brain stimulation. \nDr. Tiksnadi is currently Chief of Neurorestoration Division\, Dept. of Neurology\, Fac. of Med. at Universitas Indonesia\, Chief of Movement Disorder Division\, Dept. of Neurology\, Fac. of Med. at Universitas Indonesia\, and Chief of Brain Stimulation and Neurorestoration Lab at Cipto Mangunkusumo Hospital\, Jakarta as well as Universitas Indonesia Hospital\, Depok. \n\n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/the-great-potential-of-qps-for-optimizing-rtms-outcomes/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/September_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230801T200000
DTEND;TZID=UTC:20230801T200000
DTSTAMP:20260404T093006
CREATED:20240731T212757Z
LAST-MODIFIED:20241017T012125Z
UID:418-1690920000-1690920000@clinicaltmssociety.org
SUMMARY:Anatomy of Theta Burst
DESCRIPTION:> > Register Now <<\nYou’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Anatomy of Theta Burst featuring Dr. Bob Sammons! \nThe presentation will review the Anatomy of Theta Burst. Theta burst is gaining popularity in both research and clinical practice but the fundamental differences with rTMS make it hard for many clinicians to understand. This presentation is designed to facilitate the understanding of and ability to explain theta burst in detail. After a brief review of how theta burst was discovered\, the focus shifts to its clinical usage and advanced protocols. A review of continuous theta burst concludes the presentation. \nTake advantage of our Q&A portion at the conclusion of the webinar! \nAt the end of this presentation participants will be able to: \n\n understand why does the definition of theta burst contain both 5 Hz and 50 Hz\n explain why theta burst was originally thought to be stronger and faster than rTMS\n discuss how theta burst originated\n\n1 Hour CME Credit available \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKERS: \nBob Sammons\, MD\, PhD\, FCTMSS\n \nDr. Bob Sammons received a bachelors and master’s degree from Auburn University\, a PhD in clinical psychology from the University of North Carolina at Greensboro\, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in 1971. He practiced adult psychiatry in Grand Junction for 30+ years. He received training in Transcranial Magnetic Stimulation in 2006 from Dr. Alvaro Pascual-Leone\, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone’s intensive course in TMS in 2018. He is Medical Director for TMS Solutions with fourteen TMS offices in various locations in the West. He is on the national Clinical TMS Society Board of Directors\, sits on three national committees and is Chairman of the 2022 Annual Meeting. He has been known to cook a little BBQ. \n  \n  \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/anatomy-of-theta-burst/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/August_23_GRW_Event_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230711T180000
DTEND;TZID=UTC:20230711T190000
DTSTAMP:20260404T093006
CREATED:20240731T202715Z
LAST-MODIFIED:20241017T012733Z
UID:395-1689098400-1689102000@clinicaltmssociety.org
SUMMARY:Transcranial Magnetic Stimulation and Neuroplasticity
DESCRIPTION:> > Register Now <<\nYou're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Transcranial Magnetic Stimulation and Neuroplasticity\, featuring Dr. Sabrina Segal! \nThe field of transcranial magnetic stimulation is evolving with novel protocols to treat depression\, and explorative studies to target other therapeutic avenues for mental health. This presentation will review the neuroplastic mechanisms that underly the therapeutic effects of TMS and explain the role of neuroplasticity in TMS-treated psychiatric and neurological conditions. This talk will also examine novel explorations for TMS and memory. \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify and understand the following:  \n\nIdentify the neuroplastic mechanisms that underly the therapeutic effects of TMS\nDescribe the role of TMS and neuroplasticity in psychiatric and neurological conditions\nExplore the therapeutic potential for TMS on neuroplastic mechanisms that underly memory\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nSabrina Segal\, PhD\nDr. Segal earned her Ph.D. in Neurobiology and Behavior from the University of California\, Irvine in 2010 and her research on exercise and memory received international recognition in 2012. She completed a postdoctoral fellowship at UC Irvine\, UC Irvine Medical School Department of Anesthesiology and Children’s Hospital of Orange County (CHOC) from 2010-2014. She was a Research Professor at Arizona State University from 2014-2016\, and has taught courses in biology\, psychology\, and neurobiology at colleges and military bases in California\, Colorado and Arizona. Her research has focused on memory consolidation and enhancement via neuroplastic mechanisms. \nShe is extremely passionate about neuroscience research\, the application of research to clinical practice\, and improving education for mental health providers. In 2016\, Dr. Segal joined the Neuroscience Education Institute\, a continuing medical education company founded by world-renowned psychiatrist Dr. Stephen Stahl\, where she developed high quality educational material based on the most current neuroscience research for mental health providers globally. She specialized in neurostimulation techniques like transcranial magnetic stimulation (TMS). Dr. Segal has published many scientific peer-reviewed journal articles\, and several books. She is the author of: Beyond the Impact: An Update on the Assessment\, Prevention\, and Treatment of Neuropsychiatric Sequelae Associated with Traumatic Brain Injury and Stahl’s Illustrated: Treatments for Mood Disorders. She was also the host for the Neuroscience Education Institute podcast\, where she published nearly 200 episodes on psychiatry and related mental health topics. \nShe is most passionate about the clinical application of TMS research\, and she recently collaborated on TMS research with Dr. Robert Sammons\, which was presented as an abstract poster at the CTMSS meeting in May 2023.  Dr. Segal is currently Director of Research at Family Care Center\, a multi-state integrative mental health clinic that combines therapy\, medication management and transcranial magnetic stimulation. \n> > Register Now <<
URL:https://clinicaltmssociety.org/event/transcranial-magnetic-stimulation-and-neuroplasticity/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/07/July_23_GRWS_Slide_Banner_Full.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230606T200000
DTEND;TZID=UTC:20230606T210000
DTSTAMP:20260404T093006
CREATED:20241022T130724Z
LAST-MODIFIED:20241022T130724Z
UID:1300-1686081600-1686085200@clinicaltmssociety.org
SUMMARY:How to Understand the Exploding Evidence on New Circuit-Based TMS Targets
DESCRIPTION:You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: How to Understand the Exploding Evidence on New Circuit-Based TMS Targets\, featuring Shan Siddiqi\, MD! \nWe are currently in the midst of a rapid growth of evidence on new circuit-based TMS targets. This leaves the clinician with a challenging conundrum. When is the evidence strong enough to use a target clinically? When there is no clinical trial\, can we learn from cohort studies? How valuable are lesion studies or functional neuroimaging studies? And how do I bring together all of this information to give my patient the best possible treatment? Fortunately\, we don’t need to reinvent the wheel - there are several guidelines on how to weigh evidence across medicine. In this session\, we will discuss how to apply these guidelines to circuit-targeted brain stimulation. \nTake advantage of our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify and understand the following:  \n\nDescribe emerging approaches for targeting brain circuits with TMS\nAppraise evidence for emerging circuit-based treatment targets\nIdentify treatment targets that have strong evidence-based support\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nShan Siddiqi\, MD \n \nDr. Siddiqi’s research is focused on mapping new TMS targets for neuropsychiatric disorders based on causal mapping of human brain function and dysfunction. Using techniques such as functional connectivity MRI\, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) to alleviate psychiatric symptoms. His work has been recognized with multiple awards from the Brain & Behavior Research Foundation\, the American Neuropsychiatric Association\, the American College of Neuropsychopharmacology\, Harvard Medical School\, and many others.
URL:https://clinicaltmssociety.org/event/how-to-understand-the-exploding-evidence-on-new-circuit-based-tms-targets-2/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/June_23_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230404T200000
DTEND;TZID=UTC:20230404T210000
DTSTAMP:20260404T093006
CREATED:20241022T131421Z
LAST-MODIFIED:20241022T131421Z
UID:1302-1680638400-1680642000@clinicaltmssociety.org
SUMMARY:Deep TMS with the H7 Coil over the Dorsomedial PFC
DESCRIPTION:You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Deep TMS with the H7 Coil over the dorsomedial PFC\, featuring Aron Tendler\, MD! \nThe presentation will explain the physical capabilities and limitations of the current commercially available coils and how they relate to areas of stimulation. This presentation will also explain the level of available evidence with the H7 for OCD\, MDD\, Alcohol Use Disorder and cocaine. \nTake advantage of our Q&A portion at the conclusion of the webinar! \nAt the end of this presentation\, participants will be able to identify and understand the following:  \n\nPhysical capabilities of the commercially available coils using electrical field measurements and simulations\nEvidence for H7 and other coils for the treatment of OCD\nEvidence for H7 and other coils for the treatment of MDD\nEvidence for H7 and other coils for the treatment of Addictions\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER:\nAron Tendler\, MD\n\nDr. Aron Tendler is board certified in general psychiatry\, sleep medicine\, and obesity medicine. He sees patients thirty hours a week\, in his private practice and spends thirty hours a week on research and education as the Chief Medical Officer for BrainsWay. \nDr. Tendler's private practice is focused on helping patients who want to improve their functioning and are willing to change their treatment regimen when they are not doing well. \nDr. Tendler's research over the last twelve years has advanced the field of psychiatry forward by gaining regulatory clearance and reimbursement with effective brain-based treatments for patients with depression and obsessive compulsive disorder. He believes a greater understanding of physics and neuroscience will improve patient care and reduce stigma for patients with all neuropsychiatric disorders.
URL:https://clinicaltmssociety.org/event/deep-tms-with-the-h7-coil-over-the-dorsomedial-pfc/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/April_4_GRWS_Slide_Banner_Jan_23_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230307T200000
DTEND;TZID=UTC:20230307T210000
DTSTAMP:20260404T093006
CREATED:20241022T131720Z
LAST-MODIFIED:20241022T131720Z
UID:1304-1678219200-1678222800@clinicaltmssociety.org
SUMMARY:Emerging Transcranial Ultrasound Neuromodulation Technologies
DESCRIPTION:You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Emerging Transcranial Ultrasound Neuromodulation Technologies\, featuring Hong Chen! \nTranscranial ultrasound neuromodulation is an emerging technology with increasing clinical investigations. Ultrasound can penetrate the skull without surgery and focus its energy with high spatial precision anywhere in the brain. In addition\, ultrasound neuromodulation has the unique capability to achieve noninvasive\, spatially targeted\, and deep brain neuromodulation. This talk will introduce the state of the art of ultrasound neuromodulation and discuss emerging technology developments in this field. \nTake advantage of our live Q&A session at the conclusion of the webinar! \nAt the end of this presentation\, participants will be able to identify the following:  \n\nWhat is transcranial ultrasound neuromodulation\nWhy this technology is the state of the art\nEmerging technology developments\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER:\nHong Chen\, PhD\n\nDr. Chen is a world-leading scientist in developing innovative therapeutic ultrasound technologies and an Associate Professor of Biomedical Engineering at Washington University in St. Louis. She earned her Ph.D. degree in Bioengineering from the University of Washington in 2011. Dr. Chen was a postdoctoral research scientist in the Department of Biomedical Engineering at Columbia University from 2012 to 2015. Since joining Washington University in St. Louis in 2015\, her research has focused on developing ultrasound-brain interfacing techniques for diagnosing and treating brain diseases and understanding brain functions. Her research has been funded by NIH BRAIN Initiative\, NIBIB\, NIA\, NIMH\, NCI\, NSF\, and DoD. \nShe currently serves on the Board of Directors for the International Society of Therapeutic Ultrasound\, the IEEE International Ultrasonics technical committee\, and the Acoustical Society of America Biomedical Ultrasound technical committee. She has received numerous awards\, including the Frederic Lizzi Early Career Award from the International Society of Therapeutic Ultrasound\, the Young Investigator Award at the International Symposium on Focused Ultrasound\, and Outstanding Teaching Award.
URL:https://clinicaltmssociety.org/event/emerging-transcranial-ultrasound-neuromodulation-technologies/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/March_7_GRWS_Slide_Banner_V3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230207T200000
DTEND;TZID=UTC:20230207T210000
DTSTAMP:20260404T093006
CREATED:20241022T132218Z
LAST-MODIFIED:20241022T132218Z
UID:1306-1675800000-1675803600@clinicaltmssociety.org
SUMMARY:rTMS for Pain: From Clinical Guidelines to Practical Challenges
DESCRIPTION:This presentation will overview the current rTMS treatment guidelines for pain\, review various challenges related to the treatment for pain and headache management\, and discuss measures to overcome these highly relevant issues. \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: rTMS for Pain: From Clinical Guidelines to Practical Challenges\, featuring Albert Leung\, MD! \nEmerging evidence supports the use of rTMS for pain and headache management. However\, pain and headache rTMS treatment protocols differ in many ways from those used for depression or other psychiatric conditions. In the upcoming Grand Round presentation\, Dr. Leung\, a pain specialist\, Professor of Anesthesiology and Pain Medicine\, will overview the current rTMS treatment guideline for pain and review various challenges related to the treatment for pain and headache management and discuss measures to overcome these highly relevant issues. \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify:  \n\nThe current clinical rTMS treatment guidelines for headache and pain;\nReview practice-related issues using rTMS for pain and headache;\nDiscuss measures and identify resources to address these highly relevant issues.\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nAlbert Y. Leung\, MD\n \nDr. Leung is a Professor of Anesthesiology and Pain Medicine at the University of California\, San Diego\, School of Medicine. In addition\, he is the Director of the Center for Pain and Headache Research at the VA San Diego Healthcare System (VASDHS) and a Research Scientist for the Veteran Medical Research Foundation. \nDr. Leung receives funding from the DOD\, VA Office of Research and Development\, and NIH for his ongoing research focusing on the mechanisms and effectiveness of non-invasive brain and peripheral stimulation for nerve function restoration and headache/pain relief. He founded the first Transcranial Magnetic Stimulation (TMS) clinical unit for pain and headache treatment in the VA healthcare system over a decade ago. He now directs the Center for TMS at the VASDHS.
URL:https://clinicaltmssociety.org/event/rtms-for-pain-from-clinical-guidelines-to-practical-challenges/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/February_7_GRWS_Slide_Banner_V2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230118
DTEND;VALUE=DATE:20230119
DTSTAMP:20260404T093006
CREATED:20241107T205200Z
LAST-MODIFIED:20241108T134240Z
UID:1537-1674000000-1674086399@clinicaltmssociety.org
SUMMARY:January 18\, 2023 Town Hall Member Meeting
DESCRIPTION:January 18\, 2023 Annual Town Hall Member Meeting  \nYou’re invited to join the Clinical TMS Society for the January 18\, 2023 Annual Town Hall Member Meeting.  \nPresentation Overview:  \nJoin the Clinical TMS Society President Mohamed Abdelghani\, MBBCh\, MSc\, FRCPsych\, FCTMSS\, Executive Director Ashleigh Servadio\, and our current committee co-chairs for an update on all 2022-2023 committee projects. \nThis is your opportunity to learn more about the various goals and projects\, ask questions and provide feedback. \nDate: January 18\, 2023 \nFormat: Zoom Meeting \nThis meeting is for current members only.  \n\nSPEAKERS:  \nBob Sammons\, MD\, PhD\, CTMSS Annual Meeting Committee Co-chair\nDr. Sammons received a bachelors and master’s degree from Auburn University\, a PhD in clinical psychology from the University of North Carolina at Greensboro\, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in1971. He practiced adult psychiatry in Grand Junction for 30+ years. He received training in Transcranial Magnetic Stimulation in 2006 from Dr. Alvaro Pascual-Leone\, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone’s intensive course in TMS in 2018. He is Medical Director for TMS Solutions with fourteen TMS offices in various locations in the West. He is on the national Clinical TMS Society Board of Directors\, sits on three national committees and is Chairman of the 2022 Annual Meeting. He has been known to cook a little BBQ. \nTracy Barbour\, MD\, CTMSS Clinical Standards Committee Co-chair\nDr. Barbour is the Medical Director of the Massachusetts General Hospital Transcranial Magnetic Stimulation (TMS) clinical service and an Instructor in Psychiatry at Harvard Medical School. Dr. Barbour’s research interests focus on addressing ways of improving treatment outcomes using Transcranial Magnetic Stimulation (TMS) through individualized treatment planning. Dr. Barbour received her medical degree from Wayne State University School of Medicine in Detroit\, Michigan\, and completed psychiatry residency at MGH/McLean combined residency program. During residency\, she served as the chief resident of McLean Hospital’s Clinical Evaluation Center. \nCarlos Lowell\, DO\, CTMSS Education Co-chair\nDr. Lowell is a board-certified psychiatrist in private practice in Sandusky\, OH. He formed the fifth fully functional TMS program in Ohio in 2013 and was the first osteopathic physician to start a program in Ohio; since then\, he has been the medical director of the TMS Institute of Ohio. Dr. Lowell is a member of the Clinical TMS Society (CTMSS)\, an international organization of more than 1\,000 members whose mission is to optimize the clinical practice\, accessibility\, and awareness of TMS. He is currently serving on the membership and education committees; resident task force and has served on the clinical standards committee for the Clinical TMS Society. One of Dr. Lowell's goals is to get the word out about TMS to the osteopathic profession during his tenure\, and he says he looks forward to working with osteopathic educators across the country. \nBaron Short\, MD\, CTMSS Insurance Co-chair\nDr. Short is a Psychiatry Specialist in Charleston\, SC\, and has over 21 years of medical experience\, with extensive experience in Addiction & Substance Abuse\, and Psychotic Disorders. He graduated from the MEDICAL UNIVERSITY OF SOUTH CAROLINA in 2001 and is affiliated with MUSC Health University Medical Center. His office accepts new patients. \nIan Cook\, MD\, DLFAPA\, FCTMSS\, CTMSS Legal Business Ethics Co-chair\nDr. Cook received his medical degree from Yale and completed his residency at the UCLA Neuropsychiatric Institute (now the UCLA Semel Institute) before completing an NIMH T32 research fellowship there and joining the full-time faculty. He held the Miller Family endowed chair in Depression Research and founded the Depression Research and Clinic Program in 2006 and the TMS Service in 2009. At UCLA he was Chair of the Faculty for the School of Medicine and Chief of Staff of the Resnick Neuropsychiatric Hospital. In 2018 he left the University and launched the Los Angeles TMS Institute\, focused on providing advanced neuromodulation treatments in the community. He was a member of the Executive Committee on Practice Guidelines for the APA and is a Distinguished Life Fellow. He has served on the Board of Directors of the Clinical TMS Society since 2013\, has been co-chair of the Legal\, Business\, and Ethics committee since 2017\, and was elected to be an inaugural Fellow of the Society in 2022 \nSamir Ibrahim\, MBBS\, MPsych\, FRANZCP\, OAM\, CTMSS Membership Co-chair \nNate Upshaw\, MD\, CTMSS Outreach Committee Co-chair\nDr. Upshaw began his medical training at the University of Florida and Tulane University School of Medicine. After attaining his doctorate at Tulane\, Upshaw continued onto the University of South Florida School of Medicine\, where he completed his internship and residency in Psychiatry. While at the University of South Florida\, Dr. Upshaw\, under the stewardship of a forward-thinking chairman\, received training to practice TMS shortly after being FDA cleared in 2008. The department’s progressive approach eventually led to the university obtaining two of the first TMS chairs in the entire state of Florida. \nAngela Phillips\, PhD\, CTMSS Research Committee Co-chair\nDr. Phillips is a licensed therapist and clinical researcher and has worked in public\, private\, government\, and not-for-profit organizations across clinical and research-oriented roles. Dr. Phillips's clinical and research experience has included suicide prevention\, cognitive behavioral and mindfulness-based therapies\, teletherapy delivery\, understanding global stress during the COVID-19 pandemic\, integrated therapeutics\, and treatments such as non-invasive brain stimulation for more severe psychiatric or neurological conditions. In addition\, Dr. Phillips has co-developed and led randomized and controlled trials in neuromodulation and has provided consultation and training for new providers\, centers\, and academic centers entering collaborative psychiatric and behavioral healthcare using novel treatment interventions and approaches. Additionally\, she is excited to cohost our new podcast\, Dear Mind\, You Matter\, focusing on creating greater awareness and access to various mental health and wellness tools. \nSPECIAL COMMITTEES: \nRandy Pardell\, MD\, DLFAPA\, FCTMSS\, CTMSS FACTMS Committee Chair\nDr. Pardell is currently the Immediate Past-President of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 5 years. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course. He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice.  \nRebecca Allen\, MD\, MPH\, CTMSS Identity Committee Chair\nDr. Allen graduated with a B.A. in Psychology with honors from Stanford University. She attended Oregon Health and Science University for medical school and earned a Masters of Public Health in biostatistics and epidemiology. She completed her psychiatry residency at the Harvard Longwood Psychiatry Residency Training Program\, a joint program between Brigham and Women’s Hospital\, Beth Israel Deaconess Medical Center\, and Massachusetts Mental Health Center. She served as Chief Resident of the psychiatry consult service at Beth Israel Deaconess Medical Center. She then completed a 2-year fellowship in Neuropsychiatry at Brigham and Women’s Hospital. She has participated in research on sleep and memory consolidation\, quality of life in multiple sclerosis\, the efficacy of different TMS protocols\, EEG biomarkers of TMS response\, the RECOVER VNS trial\, and other projects. She has authored several papers. Dr. Allen has had several roles with the Clinical TMS Society\, including serving on the Board of Directors\, as the Treasurer\, as Co-Chair of the Insurance Committee\, and as Vice President. She was presented with a service award from the CTMSS in 2021. \nDebra Stultz\, MD\, CTMSS Budget & Finance\, and Structure Committee Chair\nDr. Stultz is the Director and Owner of Stultz Sleep and Behavioral Health in Barboursville\, West Virginia. Dr. Stultz earned her medical degree from Marshall University School of Medicine in Huntington\, West Virginia. She completed a residency in psychiatry and a fellowship in child/adolescent psychiatry through West Virginia University at their Charleston Division through Charleston Area Medical Center in Charleston\, West Virginia. She is board certified in psychiatry\, sleep medicine\, and behavioral sleep medicine.  With a special interest in Narcolepsy\, she treats a variety of sleep disorders and psychiatric issues.  Her specialty in psychiatry is treatment-resistant depression. She is also the editor for the Clinical TMS Society Newsletter\, on their Board of Directors\, Co-Chair of the Education Committee\, and the chairman of the TMS and Sleep Disorders Affinity Group. \nMODERATED BY:  \nMohamed Abdelghani\, MBBCh\, MSc\, FRCPsych\, FCTMSS\, CTMSS President \nDr. Abdelghani completed his post-graduate psychiatric training at South London & Maudsley NHS Foundation trust (SLaM) which is the biggest mental health trust in the UK\, a center of excellence and one of the most influential mental health organizations in the world. During his training at SLaM he worked alongside some of the most prominent professors and clinicians in the field. Dr. Abdelghani worked at the National Affective Disorders Service\, which was one of six national affective disorders units in the UK. The time he spent on the National Affective Disorders Unit and outpatient clinic equipped him with clinical skills and excellent experience to manage and treat the most treatment resistant depressed and bipolar patients. After working in the National Affective Disorders service for a year he became involved in a multicenter international cutting edge research that tested the use of Deep Brain Stimulation (DBS) to treat treatment resistant depression. He was the primary psychiatrist at King’s College London site for this study. Neurostimulation is one of his special interests and working on this study gave him the opportunity to meet and build links with leading figures in the field around the world. Another special interest of Dr. Abdelghani is Adult ADHD.  Dr Abdelghani trained at the first Adult ADHD clinic in the UK that was opened at the Maudsley Hospital in London. \nAfter finishing his higher psychiatry training at SLaM he worked as a consultant psychiatrist for almost a year at the same organization before moving to work in central London at Camden and Islington NHS Foundation Trust. At the present time he is the Lead Consultant Psychiatrist for Adult ADHD at Camden and Islington NHS Foundation Trust besides working as a consultant psychiatrist in CDAT (Complex depression\, Anxiety and Trauma) service. Dr Abdelghani continues being actively involved in research in the field of Adult ADHD and mood disorders. He has a keen interest in spreading mental health awareness and knowledge through teaching medical students\, training junior doctors\, giving lectures to fellow psychiatrists and media interviews. \n\n\n\n\n \n \n \n\n\n\n\n\n\n\nWhen\nJanuary 18th\, 2023 from  5:00 PM to  6:30 PM
URL:https://clinicaltmssociety.org/event/january-18-2023-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2023_Annual_Town_Hall_Meeting_Social_Media_V2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230103T200000
DTEND;TZID=UTC:20230103T210000
DTSTAMP:20260404T093006
CREATED:20241022T132643Z
LAST-MODIFIED:20241022T132643Z
UID:1308-1672776000-1672779600@clinicaltmssociety.org
SUMMARY:Interventional Psychiatry in Training and Clinical Practice
DESCRIPTION:This presentation will review current viewpoints on the definition and scope of practice of an interventional psychiatrist\, as well as discuss training needs\, dilemmas\, and future directions of this new subspecialty. \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Interventional Psychiatry in Training and Clinical Practice: Definitions\, Dilemmas\, and Future Directions of a Subspecialty\, featuring Tracy Barbour\, MD! Don't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to identify:  \n\nThree treatment modalities that might be in the scope of practice of an interventional psychiatrist;\nThree ways of improving access to interventional psychiatry educational opportunities;\nTwo benefits of acquiring training in more than one neuromodulation modality.\n\nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nTracy Barbour\, MD\nMedical Director\nTranscranial Magnetic Stimulation (TMS) clinical service\nMassachusetts General Hospital \n\nDr. Barbour works at the Massachusetts General Hospital as the Medical Director of Transcranial Magnetic Stimulation (TMS) clinical service\, the Associate Director of the ECT service\, and the Program Director of the Interventional Neuropsychiatry and Neuromodulation Fellowship. Dr. Barbour received her medical degree from Wayne State University School of Medicine in Detroit\, Michigan\, and completed psychiatry residency at MGH/McLean combined residency program. During residency\, she served as the chief resident of McLean Hospital’s Clinical Evaluation Center. Following residency\, Dr. Barbour was awarded the Dupont-Warren Fellowship from Harvard Medical School\, to learn advanced methods in neuroimaging and neuroscience research. Clinically\, Dr. Barbour treats patients in the TMS\, ECT\, and ketamine clinical services. Her research interests focus on addressing ways of improving treatment outcomes using Transcranial Magnetic Stimulation (TMS) through individualized treatment planning. Dr. Barbour is a member of the Clinical TMS Society and services as co-chair of the Clinical TMS Society’s clinical standards committee.
URL:https://clinicaltmssociety.org/event/interventional-psychiatry-in-training-and-clinical-practice/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/January_23_GRWS_Slide_Banner_FULL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221206T200000
DTEND;TZID=UTC:20221206T210000
DTSTAMP:20260404T093006
CREATED:20241022T133248Z
LAST-MODIFIED:20241022T133248Z
UID:1310-1670356800-1670360400@clinicaltmssociety.org
SUMMARY:If it’s not a chemical imbalance\, then what do I have?
DESCRIPTION:This presentation will summarize recent findings on the neurobiology of depression\, and distill these findings into a narrative form that is more clearly comprehensible to practitioners and patients alike. Updated explanatory models of depression may help patients better understand their own illness\, make sense of the symptoms they experience\, and make better informed choices about which treatment options to pursue\, as neuromodulation treatments enter increasingly widespread use in the community. \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: \n"If it’s not a chemical imbalance\, then what do I have?”\, featuring Jonathan Downar\, MD\, PhD\, FRCPC! \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to:  \n(1) To review recent advances in our understanding of the neurobiology of depression. \n(2) To understand how these advances shed light on the mechanisms of old and new treatments for depression. \n(3) To acquire more accurate and more comprehensible updated narratives for explaining depression and its treatment to patients and members of the lay public \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nJonathan Downar\, MD\, PhD\, FRCPC \n \nDr Jonathan Downar is an Associate Professor in Psychiatry and a Senior Fellow at Massey College at the University of Toronto.  His work over the last 25 years has spanned the translational spectrum from basic science work using functional neuroimaging to randomized controlled trials of novel treatment protocols for transcranial magnetic stimulation.  He is the senior author of the widely cited THREE-D study\, published in Lancet in 2018\, that led to formal FDA approval for 3 minute theta-burst TMS in depression.  He enjoys close collaborations with colleagues in the United States\, Canada\, Europe\, and Australia on projects dedicated to making TMS treatments more effective\, and above all more accessible\, for patients with depression and other psychiatric disorders.  The long-term objective of this work is to achieve large and measurable reductions in the worldwide prevalence of depression and mental illnesses\, within our lifetimes\, via a new generation of safe\, scalable\, and effective brain-based interventions.
URL:https://clinicaltmssociety.org/event/if-its-not-a-chemical-imbalance-then-what-do-i-have/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/December_22_GRWS_Slide_Banner_April_22_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20221101T150000
DTEND;TZID=UTC:20221101T160000
DTSTAMP:20260404T093006
CREATED:20241022T133502Z
LAST-MODIFIED:20241022T133502Z
UID:1312-1667314800-1667318400@clinicaltmssociety.org
SUMMARY:Getting to the Heart of Precision-TMS: Brainmarkers and Heart-Brain Coupling to optimize TMS clinical outcomes.
DESCRIPTION:Given relatively modest remission rates for all antidepressant treatments available\, there is a need for approaches that help tailor existing treatments to the individual in order to improve remission rates. In addition\, such techniques should be clinically actionable and well validated in blinded out-of-sample validations. Here we introduce the concept of Stratified Psychiatry\, that is better suited for implementation in clinical practice\, and demonstrate that Brainmarker-I\, an EEG biomarker\, can successfully help stratify patients between 1-Hz right and 10-Hz left rTMS\, as well as for ECT and various other antidepressant treatments\, as a clinically actionable stratification marker.\nFurthermore\, a novel update of NCG-TMS called Heart-Brain Coupling is introduced that provides real time evidence of frontal-vagal activation\, simply measured using an iPhone app. This technique not only helps identify the right target for frontal-vagal activation\, but also provides frontal excitability thresholds (which are known to differ substantially from motor-thresholds). \nYou’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Getting to the heart of precision-TMS: Brainmarkers and Heart-Brain Coupling to optimise TMS clinical outcomes\, featuring Martijn Arns\, PhD! \nDon't miss out on our Q&A portion of the webinar! \nAt the end of this presentation\, participants will be able to:  \n(1) How specific TMS stimulation can directly influence heart rate via heart-brain coupling; \n2) How the motor threshold is different from frontal excitability thresholds; and \n3) How specific EEG frequencies can be instrumental in stratifying patients between 1-Hz and 10-Hz rTMS. \nFormat: On-Demand \nCost: Members: $25 | Non-members $50 | Student Members FREE \n\nSPEAKER: \nMartijn Arns\, PhD \n \nDr. Arns graduated in the late 90’s as a biological psychologist and in 2011 received his PhD at Utrecht University on the topic of 'EEG-based personalized medicine for ADHD and depression'. He is founder and research director at the non-profit Brainclinics Foundation\, associate professor at Maastricht University\, Section Brain Stimulation and Cognition and scientific adviser to neurocare group.
URL:https://clinicaltmssociety.org/event/getting-to-the-heart-of-precision-tms-brainmarkers-and-heart-brain-coupling-to-optimize-tms-clinical-outcomes/
CATEGORIES:All Events,Grand Rounds Webinar
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/10/November_22_GRWS_Slide_Banner_April_22_GRWS_Slide_Banner_300x150.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220315
DTEND;VALUE=DATE:20220316
DTSTAMP:20260404T093006
CREATED:20241107T204632Z
LAST-MODIFIED:20241108T134415Z
UID:1526-1647302400-1647388799@clinicaltmssociety.org
SUMMARY:March 2022 New Member Welcome Meeting
DESCRIPTION:March 15th\, 2022 New Member Welcome Meeting  \nYou’re invited to join the Clinical TMS Society for the March 15\, 2022 New Member Welcome Meeting.  \nPresentation Overview:  \nIntroductory Orientation Meeting for New Members of the Clinical TMS Society \nThe Membership Committee of the CTMSS has initiated a new program of bi-yearly virtual orientation meetings to assist new members in how to most effectively engage with our Society and to obtain the most benefit from their CTMSS membership. The meeting will be led by our President Randy Pardell\, MD\, DLFAPA\, and Membership Committee Co-chair Rebecca Cohen\, MD. \nObjectives:  \n\nLearn the history of CTMSS and its mission statement\, bylaws\, committee structure and administration.\nLearn the different levels of membership and how to maximize your membership experience.\nLearn educational opportunities within CTMSS programs.\nUnderstand our website and how to navigate its rich content.\nLearn how to keep up to date with the ever changing landscape of TMS therapy and the burgeoning activities of our society through our website and society activities.\n\nDate: March 15\, 2022 \nTime: 5:00 pm PDT\, 8:00 pm EDT \nFormat: LIVE \nThis meeting is for current members only. \n\nSPEAKERS:  \nRebecca Cohen\, MD\, Membership Committee Co-chair\nDr. Cohen has been an active member of the Clinical TMS Society and now serves as a Board of Director and the Co-Chair of the Membership Committee \nDr. Cohen earned her Bachelor of Science in Biopsychology at Tufts University in Medford\, Mass.\, and her Master of Medical Science at Boston University’s Graduate School of Arts & Sciences based on research completed at Harvard Medical School. Dr. Cohen completed her medical degree at Boston University School of Medicine where she was recipient of the psychiatry department’s Malamud Award for Excellence. She completed her Psychiatry Residency training at Georgetown University Medical Center in Washington\, D.C.\, where she served as Chief Psychiatry Resident at Georgetown Hospital during her final year. \nFrom 2001 to 2012\, Dr Cohen joined the staff at Newton Wellesley Psychiatry in Massachusetts\, specializing in adult psychiatry and psychopharmacology. She pioneered one of the first private practice TMS Programs in MA in 2010 and was the site contributor to the TMS National Outcome Study.  After relocating to Sarasota\, Florida in 2012\, she became TMS director in a private practice and then in 2018 joined Greenbrook TMS Neurohealth Centers where she serves as Central Florida Regional Medical Director\, providing direct clinical care and patient advocacy in her role.  \nIn addition to her TMS work\, Dr. Cohen owns and manages her private practice providing concierge level of care throughout Central Florida.  She has excelled in her role as Clinical Assistant Professor for psychiatry clerkship instructing students at Florida State University School of Medicine.  Dr Cohen has been recognized for excellence in teaching and clinical practice throughout her career. Most recently\, Dr. Cohen has been honored as a Doctor of Distinction by Sarasota Scene Magazine in 2018 and 2020\, recognized as a Top Doctor by Sarasota Magazine and was inducted into Marquis Who’s Who in June 2020.  \nRandy Pardell\, MD\, DLFAPA\, CTMSS President\nDr. Pardell is currently the President of the Clinical TMS Society. He has served on the Board of Directors of CTMSS for the past 4 years and has been elected to the Executive Committee as Member at Large for two terms and Vice President.  He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course as well. He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. \nDr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. \nDr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice.  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWhen\nMarch 15th\, 2022 5:00 PM to March 15th\, 2024 6:00 PM
URL:https://clinicaltmssociety.org/event/march-2022-new-member-welcome-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2022_March_NMWM_Thumbnail.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220112
DTEND;VALUE=DATE:20220113
DTSTAMP:20260404T093006
CREATED:20241107T204431Z
LAST-MODIFIED:20241108T134436Z
UID:1523-1641945600-1642031999@clinicaltmssociety.org
SUMMARY:January 12\, 2022 Town Hall Member Meeting
DESCRIPTION:January 12\, 2022 Annual Town Hall Member Meeting  \nYou’re invited to join the Clinical TMS Society for the January 12\, 2022 Annual Town Hall Member Meeting.  \nPresentation Overview:  \nJoin the Clinical TMS Society President Randy Pardell\, MD\, DLFAPA\, Executive Director Ashleigh Sevadio and our current committee co-chairs for an update on all 2021-2022 committee projects. \nThis is your opportunity to learn more about the various goals and projects\, ask questions and provide feedback. \nDate: January 12\, 2022 \nFormat: Zoom Meeting \nThis meeting is for current members only.  \n\nSPEAKERS:  \nJohn O'Reardon\, MD\, CTMSS Annual Meeting Committee Co-chair\nDr. O’Reardon has been in practice as a psychiatrist for 30 years. He completed his residency training at Penn and Fellowships in Psychopharmacology & Cognitive Therapy (including training at the Beck Institute). In his clinical work as a faculty member at Penn he focused on treatment-resistant mood disorders and neuromodulation. This is the development of brain devices to stimulate the brain and treat mood disorders. These devices\, which are increasing all the time\, include transcranial magnetic stimulation (TMS)\, deep brain stimulation (DBS)\, vagus nerve stimulation (VNS)\, EEG-synchronized TMS (sTMS)\, deep TMS (dTMS) and transcranial direct current stimulation (tDCS). \nDr. O’Reardon was an active educator at Penn and over the years helped train more than a hundred psychiatry residents. He taught courses on neuromodulation\, mood disorders and the History of Psychiatry. He has been a recipient of numerous teaching awards including the Earl Bond Award for excellence in teaching. He has been a frequent presenter at the annual meeting of the American Psychiatric Association (APA). Most recently he has presented a symposium on historical figures and mood disorders called Art\, Politics and Creativity: Resilience in the Face of Great Odds – including Abraham Lincoln\, Vincent Van Gogh\, Winston Churchill and Sylvia Plath. \nDr. O’Reardon has been an active and productive researcher during his career. He has authored over a hundred publications in his career encompassing new brain devices (TMS\, sTMS\, VNS\, DBS and tDCS)\, major depression\, bipolar disorder\, ECT and the night eating syndrome. He has been a lead investigator in many cutting edge clinical trials of new treatments for patients. He is first author on the primary trial that led to FDA approval for TMS as new exciting treatment for major depression. His current research work is with another exciting emerging treatment modality for major depression\, namely tDCS. \nRobert Sammons\, MD\, CTMSS Annual Meeting Committee Co-chair\nDr. Bob Sammons received a bachelor's and master's degree from Auburn University\, a PhD in clinical psychology from the University of North Carolina at Greensboro\, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in 1971. He has practiced adult psychiatry in Grand Junction for 29 years. He received training in TMS in 2006 from Dr. Alvaro Pascual-Leone\, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone's intensive course in TMS in 2018. He is Medical Director for TMS Solutions with TMS offices in various locations in the West.  \nMichelle Cochran\, MD\, CTMSS Education Committee Co-chair\nDr. Cochran received her undergraduate degree from Centre College in Danville\, Kentucky\, and completed her medical training at the University of Louisville School of Medicine. She received postgraduate medical education at Vanderbilt University Medical Center in Nashville\, TN\, where she completed a residency in Psychiatry. During this residency she was Chief Resident. Additionally\, she completed the Management Program for Physicians and Senior Healthcare Administrators at Vanderbilt University's Owen School of Management. A diplomat of the American Board of Psychiatry and Neurology\, Dr. Cochran is a member of the Tennessee Psychiatric Association\, Tennessee Medical Association\, Nashville Academy of Medicine\, the Clinical TMS Society and Tennessee Women in Medicine. Since her residency years\, she has been a member of the American Psychiatric Association\, and in early 2011\, she was inducted as a Fellow in this organization. Dr. Cochran has been on the Clinical Faculty in the Department of Psychiatry at Vanderbilt University Medical Center since 1996 and has lectured to undergraduate\, graduate\, and postgraduate students as well as private practitioners. \nFor over 20 years\, she has been active on numerous advisory boards professionally and personally. Before retiring from inpatient psychiatric care and establishing her outpatient private practice\, she was the medical director for many psychiatric units and programs in the Middle Tennessee area. Dr Cochran currently works in a private practice in Nashville. She has experience treating a variety of psychiatric conditions\, using therapy\, counseling\, medicines\, neuro-modulation\, and integrative care options. Dr. Cochran and her staff have trained extensively in the use of repetitive Transcranial Magnetic Stimulation (rTMS) including training at Harvard (Berenson Allen Non-Invasive Brain Stimulation Clinic)\, Duke and other training. Dr Cochran has spoken nationally on the use of rTMS in a clinical setting in both industry and continuing education venues. Dr. Cochran has been a integral part of the Clinical TMS Society\, currently serving on the Education & Annual Meeting Committees. \nMartha Koo\, MD\, CTMSS Research Committee Co-chair\nDr. Martha B. Koo\, M.D.\, completed her undergraduate studies at Princeton University and her medical training at the David Geffen School of Medicine at UCLA. She obtained her psychiatry residency training at the UCLA Resnick Neuropsychiatric Institute and her subsequent psychoanalytic training at the New Center for Psychoanalysis. She is double Board Certified in Psychiatry and Addiction Medicine. For over 25 years\, Dr. Koo has enjoyed her private practice\, providing outpatient psychotherapy\, psychoanalysis and pharmacological treatment for individuals\, couples and families. A pioneer in the development and application of Transcranial Magnetic Stimulation (TMS)\, Dr. Koo opened the South Bay TMS Therapy Center in 2009. She is currently the founder and CEO of Neuro Wellness Spa\, where she offers TMS\, Magnetic E-Resonance therapy\, iv ketamine\, iv nutrition\, and photobiomodulation as novel interventions for treatment-resistant mental illness.  In pursuit of additional interventions for wellness\, she is currently studying psychedelic assisted psychotherapy at the California lnstitute of Integral Studies. Dr. Koo is also the Medical Director at Clear Recovery Center\, a residential detox and intensive outpatient treatment center for individuals struggling with mental health\, addiction and dual diagnoses. She is on the Board of Directors of the Clinical TMS Society and the Beach Cities Health District and is an active lecturer at the New Center for Psychoanalysis. \nSaydra R Wilson\, MD\, CTMSS Outreach Committee Co-chair\nDr\, Saydra Wilson is an Assistant Professor at the University of Minnesota-Twin Cities where she combines her clinical interventional psychiatry work in ECT and TMS with her research interests in TMS mechanisms and biomarkers for TMS response. She has been a member of the Clinical TMS Society since 2018 and is currently serving on the Board of Directors and enjoy's her role as Outreach committee co-chair and  member of the Education Committee. \nW. Nate Upshaw\, MD\, CTMSS Outreach Committee Co-chair\nDr. Upshaw began his medical training at the University of Florida and Tulane University School of Medicine. After attaining his doctorate at Tulane\, Upshaw continued onto the University of South Florida School of Medicine\, where he completed his internship and residency in Psychiatry. While at the University of South Florida\, Dr. Upshaw\, under the stewardship of a forward-thinking chairman\, received training to practice TMS shortly after being FDA cleared in 2008. The department’s progressive approach eventually led to the university obtaining two of the first TMS chairs in the entire state of Florida.  \nF. Andrew Kozel\, MD\, MSCR\, CTMSS Clinical Standards Committee Co-chair\nDr. Kozel is Professor and the Mina Jo Powell Endowed Chair for Neurological Sciences at Florida State University College of Medicine where he directs FSU Neuromodulation at Innovation Park\, is the Medical Director for FSU Behavioral Health at Apalachee Center and Co-Director for the FSU Mood and Anxiety Center of Excellence in the Department of Behavioral Sciences and Social Medicine. Kozel's work with neuromodulation techniques like TMS has included research\, clinical care\, teaching\, and dissemination for over 20 years. His research uses brain imaging and brain stimulation to better understand and treat neuropsychiatric disorders with the focus of improving the lives of patients with these devastating disorders. \nRichard Bermudes\, MD\, CTMSS Insurance Committee Co-chair\nRichard Bermudes\, M.D.\, is the chief medical officer at Mindful Health Solutions in California and a volunteer assistant clinical professor of psychiatry at the University of California\, San Francisco. He is a co-founder of the Clinical TMS Society\, former president and board member and currently co-chairs the insurance committee. His clinical practice includes ECT\, TMS\, Ketamine and Esketamine. He has a column with Psychiatric News on Interventional Psychiatry and he is also the co-editor of Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice from APA Publishing. \nKen Goolsby\, MD\, CTMSS Membership Committee Co-chair\nKenneth E. Goolsby\, M.D. has been in private practice in Gainesville since 1987. As a child\, adolescent and adult psychiatrist\, he provides diagnostic evaluations\, individual and family psychotherapy\, medication evaluation and management\, crisis intervention\, and chemical dependency evaluations. Dr. Goolsby provides inpatient hospital care as well as outpatient care. \nDr. Goolsby earned his bachelor's degree at the University of Georgia and his medical degree at the Medical College of Georgia. He completed his psychiatric residency at the William S. Hall Psychiatric Institute Emory University. He then completed his child psychiatry fellowship at William S. Hall Psychiatric Institute. He is a diplomate of the American Board of Psychiatry and Neurology. \nIan Cook\, MD\, CTMSS Legal\, Business\, and Ethics Committee Co-chair\nIan A. Cook\, M.D. is Founder and Director of the Los Angeles TMS Institute\, Inc.\, and Professor Emeritus of Psychiatry and Biobehavioral Sciences in UCLA’s David Geffen School of Medicine\, where he previously held the Miller Family Endowed Chair in Depression Research\, was Director of the UCLA Depression Research & Clinic Program\, and was the Founding Director of the UCLA TMS Service. Dr. Cook earned his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute\, where he also was an NIMH-funded research fellow\, before joining the faculty. Dr. Cook served on the Executive Committee on Practice Guidelines of the American Psychiatric Association and guided the electronic dissemination of their evidence-based guidelines in psychiatry. A board-certified Psychiatrist\, he has also served as an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America\, Who's Who in the World\, and Best Doctors. He is the author of numerous publications on brain function in mental illness and in aging and holds several dozen patents on biomedical devices and methods. \nMahmound Okasha\, MD\, CTMSS Legal\, Business\, and Ethics Committee Co-chair\nDr. Mahmoud Okasha is a board certified psychiatrist. He has been in clinical practice since 1977. He became an Associate Clinical Professor of Psychiatry after completing his residency at Yale Medical School department of psychiatry. Dr. Okasha is the Medical Director of Comprehensive Psychiatric Care. \nHe has always been interested in research and began his career in London\, England in 1970 where he was doing his residency in psychiatry at the Westminster Medical School. Dr. Okasha has been a primary investigator since 2000 at CPC where he has conducted numerous trials. He is also interested in clinical work with anxiety and treatment-resistant depression\, which led to his initiation of TMS at CPC. \nMODERATED BY:  \nRandy Pardell\, MD\, DLFAPA CTMSS President \nDr. Pardell is currently the President of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 4 years and has been elected to the Executive Committee as Member at Large for two terms and now as President. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course.   He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice.  \n\n\n\n\n \n \n \n\n\n\n\n\n\n\nWhen\nJanuary 12th\, 2022 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/january-12-2022-town-hall-member-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2022_Annual_Town_Hall_Member_Meeting_Thumbnail_V6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210922
DTSTAMP:20260404T093006
CREATED:20241107T204331Z
LAST-MODIFIED:20241108T134502Z
UID:1521-1632182400-1632268799@clinicaltmssociety.org
SUMMARY:September 2021 New Member Welcome Meeting
DESCRIPTION:September 21\, 2021 New Member Welcome Meeting  \nYou’re invited to join the Clinical TMS Society for the September 21\, 2021 New Member Welcome Meeting.  \nPresentation Overview:  \nIntroductory Orientation Meeting for New Members of the Clinical TMS Society \nThe Membership Committee of the CTMSS has initiated a new program of bimonthly virtual orientation meetings to assist new members in how to most effectively engage with our Society and to obtain the most benefit from their CTMSS membership. The meeting will be led by our President Randy Pardell\, MD\, DLFAPA\, and Membership Committee Co-chair Rebecca Cohen\, MD. \nObjectives:  \n\nLearn the history of CTMSS and its mission statement\, bylaws\, committee structure and administration.\nLearn the different levels of membership and how to maximize your membership experience.\nLearn educational opportunities within CTMSS programs.\nUnderstand our website and how to navigate its rich content.\nLearn how to keep up to date with the ever changing landscape of TMS therapy and the burgeoning activities of our society through our website and society activities.\n\nDate: September 21\, 2021 \nTime: 5:00 pm PDT\, 8:00 pm EDT \nFormat: LIVE \nThis meeting is for current members only. \n\nSPEAKERS:  \nRebecca Cohen\, MD\, Membership Committee Co-chair\nDr. Cohen has been an active member of the Clinical TMS Society and now serves as the Co-Chair of the Membership Committee and begins her tenure on the National Board in June 2021. \nDr. Cohen earned her Bachelor of Science in Biopsychology at Tufts University in Medford\, Mass.\, and her Master of Medical Science at Boston University’s Graduate School of Arts & Sciences based on research completed at Harvard Medical School. Dr. Cohen completed her medical degree at Boston University School of Medicine where she was recipient of the psychiatry department’s Malamud Award for Excellence. She completed her Psychiatry Residency training at Georgetown University Medical Center in Washington\, D.C.\, where she served as Chief Psychiatry Resident at Georgetown Hospital during her final year. \nFrom 2001 to 2012\, Dr Cohen joined the staff at Newton Wellesley Psychiatry in Massachusetts\, specializing in adult psychiatry and psychopharmacology. She pioneered one of the first private practice TMS Programs in MA in 2010 and was the site contributor to the TMS National Outcome Study.  After relocating to Sarasota\, Florida in 2012\, she became TMS director in a private practice and then in 2018 joined Greenbrook TMS Neurohealth Centers where she serves as Central Florida Regional Medical Director\, providing direct clinical care and patient advocacy in her role.  \nIn addition to her TMS work\, Dr. Cohen owns and manages her private practice providing concierge level of care throughout Central Florida.  She has excelled in her role as Clinical Assistant Professor for psychiatry clerkship instructing students at Florida State University School of Medicine.  Dr Cohen has been recognized for excellence in teaching and clinical practice throughout her career. Most recently\, Dr. Cohen has been honored as a Doctor of Distinction by Sarasota Scene Magazine in 2018 and 2020\, recognized as a Top Doctor by Sarasota Magazine and was inducted into Marquis Who’s Who in June 2020.  \nRandy Pardell\, MD\, DLFAPA\, CTMSS President\nDr. Pardell is currently the President of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 4 years and has been elected to the Executive Committee as Member at Large for two terms and now as Vice President. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course.   He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice. 
URL:https://clinicaltmssociety.org/event/september-2021-new-member-welcome-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2021_May_NMWM_Thumbnail_v2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210715
DTEND;VALUE=DATE:20210716
DTSTAMP:20260404T093006
CREATED:20241107T204203Z
LAST-MODIFIED:20250312T184309Z
UID:1518-1626307200-1626393599@clinicaltmssociety.org
SUMMARY:2021 Poster Session: A Virtual Experience
DESCRIPTION:We are excited to announce that the 2021 posters will be available for online viewing through December 31\, 2021. As the window to view the posters are limited\, we encourage everyone to register asap\, to receive the max allotted time.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWe have a total of 29 authors/presenters sharing their critical insights and research findings. \nEarn up to a max of 7.25 hours of CME depending on how many posters you choose to view. \nInstructions on how to access the posters and obtain CME will be included in your confirmation email. \nCosts: \n\nCTMSS Members: $25 USD\nNon-Members: $85 USD\n\nAll registrations will be checked for membership. \n\nAcknowledgment of Financial Commercial Support\nNo financial commercial support was received for this educational activity. \nAcknowledgment of In-Kind Commercial Support\nNo in-kind commercial support was received for this educational activity. \nSatisfactory Completion\nLearners must review each poster chosen and take up to 15 minutes to absorb the information and complete an evaluation form to receive a certificate of completion. \nComplete all posters you wish to view before completing the evaluation. \nIf you are seeking continuing education credit for a specialty not listed below\, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. \n\n\nPhysicians \n \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. \nCredit Designation Statement – Amedco LLC designates this enduring material for a maximum of 7.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nObjectives - After Attending This Program You Should Be Able To \n\nIdentify evidence for various TMS treatment approaches compared to standard TMS approach\nDiscuss the effectiveness of TMS in various populations and settings\nDiscuss predictive biomarkers and/or clinical markers of response to repetitive transcranial magnetic stimulation (rTMS) treatment\n\nDisclosure of Conflict of Interest \nThe following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest\, and have been resolved. (C7 SCS 6.1-­‐6.2\, 6.5) \nAll individuals in a position to control the content of CE are listed on the website. If their name is not listed below\, they disclosed that they had no financial relationships with a commercial interest. \n\n\n\nFirst Name\nLast Name\nCommercial Interest: Relationship\n\n\n\n\nScott\nAaronson\nNeuronetics:Research Grant Site Principal Investigator\,Janssen:Consultant\,Sage Therapeutics:Consultant\,Compass Pathways:Research Grant Site Principal Investigator\,Genomind:Scientific/Medical Advisory Board Member\,LivaNova:Consultant\,Neurolief:Consultant\,Neuronetics:Consultant\,Compass Pathways:Research Grant Overall Principal Investigator\n\n\nPaul\nCroarkin\nNeuronetics\, Inc:Research Grant Site Principal Investigator\,Pfizer\, Inc:Research Grant Overall Principal Investigator\,Assurerx Health:Other\,Procter & Gamble Company:Consultant\,Sunovian :Scientific/Medical Advisory Board Member\,NeoSync:Research Grant Site Principal Investigator\,MagVenture: Equipment Support \,Myriad Neuroscience:Consultant\,Engrail Therapeutics:Scientific/Medical Advisory Board Member\,Neuronetics:Equipment Support\n\n\nNancy\nDonachie\nSmart Health & Wellness Centers:Stock Shareholder\,Salience TMS Neuro Solutions:Scientific/Medical Advisory Board Member\,Smart Health & Wellness Centers:Scientific/Medical Advisory Board Member\n\n\nDavid\nDunner\nNeuronetics:Other Financial or Material Support/consultant\,Cyberonics/Livanova:Other Financial or Material Support/Research support\,Janssen:Consultant\n\n\nTodd\nHutton\nNeuronetics:Consultant\,Southern California TMS Center:Stock Shareholder\n\n\nJoseph\nKriske\nSalience TMS Neuro Solutions:Stock Shareholder\n\n\nAdonis\nMaiquez\nCommercial interest:Own BrainsWay TMS machine\n\n\nLucian\nManu\nResearch Funding:Research Grant Site Principal Investigator\n\n\nLeigh\nNeal\nSmart TMS:Medical Director of Smart TMS\n\n\nLeigh\nNeal\nSmart TMS:Medical Director of Smart TMS\n\n\nRandy\nPardell\nNeuronetics :Co-marketing\n\n\nRandy\nPardell\nNeuronetics :Co-marketing\n\n\nKenny\nPerez\nSuccessTMS:Consultant\n\n\nYiftach\nRoth\nBrainsWay Ltd.:Stock Shareholder\n\n\nDebra\nStultz\nJazz Pharmaceticuls:Speakers Bureau\,Harmony Biosciences:Speakers Bureau\n\n\nARON\nTENDLER\nBrainsway:Consultant\,Brainsway:Stock Shareholder\n\n\n\n\n\n\n\n\nWhen\nJuly 15th\, 2021 8:00 AM to July 17th\, 2021 11:59 PM\n\n\n\nContact\n\nPhone: 8453923238\nEmail: info@clinicaltmssociety.org\nEmail: info@clinicaltmssociety.org\n\n\n\n\nVirtual Poster Session Costs\n\n\n\n\nVirtual Poster Session Costs\n\n\n\nCTMSS Member\n$25.00\n\n\nNon-Member\n$85.00\n\n\nComplimentary Registration\n\n\n\nRegistered for Annual Meeting\n$0.00\n\n\nRegistered for Live Stream\n$0.00\n\n\n\n\n\n\n\n\n\n\n\n\n 
URL:https://clinicaltmssociety.org/event/2021-poster-session-a-virtual-experience/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/png:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Clinical-TMS-Feature-Image-Logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210518
DTEND;VALUE=DATE:20210519
DTSTAMP:20260404T093006
CREATED:20241107T203928Z
LAST-MODIFIED:20250312T183304Z
UID:1516-1621296000-1621382399@clinicaltmssociety.org
SUMMARY:May 18\, 2021 New Member Welcome Meeting 
DESCRIPTION:May 18\, 2021 New Member Welcome Meeting  \nYou’re invited to join the Clinical TMS Society for the May 18\, 2021 New Member Welcome Meeting.  \nPresentation Overview:  \nIntroductory Orientation Meeting for New Members of the Clinical TMS Society \nThe Membership Committee of the CTMSS has initiated a new program of bimonthly virtual orientation meetings to assist new members in how to most effectively engage with our Society and to obtain the most benefit from their CTMSS membership. The meeting will be led by our Vice President/President-Elect Randy Pardell\, MD\, DLFAPA\, and Membership Committee Co-chair Rebecca Cohen\, MD. \nObjectives:  \n\nLearn the history of CTMSS and its mission statement\, bylaws\, committee structure and administration.\nLearn the different levels of membership and how to maximize your membership experience.\nLearn educational opportunities within CTMSS programs.\nUnderstand our website and how to navigate its rich content.\nLearn how to keep up to date with the ever changing landscape of TMS therapy and the burgeoning activities of our society through our website and society activities.\n\nDate: May 18\, 2021 \nFormat: ON-DEMAND \nThis meeting is for current members only. \n\nSPEAKERS:  \nRebecca Cohen\, MD\, Membership Committee Co-chair\nDr. Cohen has been an active member of the Clinical TMS Society and now serves as the Co-Chair of the Membership Committee and begins her tenure on the National Board in June 2021. \nDr. Cohen earned her Bachelor of Science in Biopsychology at Tufts University in Medford\, Mass.\, and her Master of Medical Science at Boston University’s Graduate School of Arts & Sciences based on research completed at Harvard Medical School. Dr. Cohen completed her medical degree at Boston University School of Medicine where she was recipient of the psychiatry department’s Malamud Award for Excellence. She completed her Psychiatry Residency training at Georgetown University Medical Center in Washington\, D.C.\, where she served as Chief Psychiatry Resident at Georgetown Hospital during her final year. \nFrom 2001 to 2012\, Dr Cohen joined the staff at Newton Wellesley Psychiatry in Massachusetts\, specializing in adult psychiatry and psychopharmacology. She pioneered one of the first private practice TMS Programs in MA in 2010 and was the site contributor to the TMS National Outcome Study.  After relocating to Sarasota\, Florida in 2012\, she became TMS director in a private practice and then in 2018 joined Greenbrook TMS Neurohealth Centers where she serves as Central Florida Regional Medical Director\, providing direct clinical care and patient advocacy in her role.  \nIn addition to her TMS work\, Dr. Cohen owns and manages her private practice providing concierge level of care throughout Central Florida.  She has excelled in her role as Clinical Assistant Professor for psychiatry clerkship instructing students at Florida State University School of Medicine.  Dr Cohen has been recognized for excellence in teaching and clinical practice throughout her career. Most recently\, Dr. Cohen has been honored as a Doctor of Distinction by Sarasota Scene Magazine in 2018 and 2020\, recognized as a Top Doctor by Sarasota Magazine and was inducted into Marquis Who’s Who in June 2020.  \nRandy Pardell\, MD\, DLFAPA\, CTMSS President-Elect\nDr. Pardell is currently the Vice President/President-elect of the Clinical TMS Society.  He has served on the Board of Directors of CTMSS for the past 4 years and has been elected to the Executive Committee as Member at Large for two terms and now as Vice President. He has been past Chairman of the Outreach Committee and has served on the Membership and Education Committees. He has been a returning lecturer for the CTMSS Pulses Course.   He has been practicing TMS therapy since 2009. He co-wrote the first lay book on TMS called 3000 Pulses. Dr. Pardell is an honors graduate of the University of Pennsylvania and New York University School of Medicine. He completed his residency and chief residency at the St. Luke’s Roosevelt Medical Center and Post-Doctoral Fellowship at Columbia University where he performed smoking cessation research with Alexander Glassman MD. After graduation from his psychiatric training\, Dr. Pardell moved up with his wife to the beautiful Hudson Valley\, New York to start a practice and raise a family. Dr. Pardell is a Distinguished Life Fellow of the American Psychiatric Association and has been a past President of the Mid-Hudson Psychiatric Society and had been its Program Director for over a decade. Dr. Pardell founded Riverview Psychiatric Medicine\, PC and TMS Center of the Hudson Valley and leads an active group psychiatric and TMS practice.  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWhen\nMay 18th\, 2021 from  5:00 PM to  6:00 PM
URL:https://clinicaltmssociety.org/event/may-18-2021-new-member-welcome-meeting/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/Grand-Rounds.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210317
DTEND;VALUE=DATE:20210318
DTSTAMP:20260404T093006
CREATED:20241107T195618Z
LAST-MODIFIED:20241108T134524Z
UID:1506-1615939200-1616025599@clinicaltmssociety.org
SUMMARY:How to Best Utilize the New CTMSS Recommended OCD Coverage Policy
DESCRIPTION:>>WATCH NOW<<\nPresentation Overview:  \nThe webinar will review the key elements contained in the recommended coverage policy for Transcranial Magnetic Stimulation for the treatment of patients with treatment-resistant obsessive-compulsive disorder. Indication for coverage\, patient selection criteria including limitations\, and utilization guidelines and recommended TMS protocol will also be reviewed. At the end of the webinar\, providers will have a better understanding of how to utilize the coverage policy to advocate for their OCD patients. \nLearning Objectives: \n\nUnderstand the content in the policy;\nUnderstand the recommended patient selection criteria;\nUnderstand the clinical evidence to support the policy;\nUnderstand how to use the policy as a part of your initial payer coverage requests\, calls and/or meetings with medical directors and peer to peer conversations and appeals.\n\nDate: March 17\, 2021 \nTime: 5:00 pm PDT / 8:00 pm EDT \nFormat: ON-DEMAND \n*This event is FREE for CTMSS Members Only.  \n\nSPEAKERS:  \nCarlene MacMillan\, MD \nCarlene MacMillan\, MD is the co-Founder and CEO of Brooklyn Minds Psychiatry\, a multidisciplinary team-based multi-site practice in the NYC Region. She is a graduate of Harvard College and Harvard Medical School and completed her adult psychiatry residency and child and adolescent fellowship at Massachusetts General Hospital/McLean Hospital.  In her work at Brooklyn Minds\, she has built a robust deep TMS program over the past 4 years. Brooklyn Minds was one of the first practices in the country to offer deep TMS for OCD upon FDA clearance. As a member of the CTMSS Insurance Committee\, she focuses primarily on advocating for appropriate OCD coverage policies as her team at Brooklyn Minds has been at the forefront of obtaining insurance coverage from commercial and Medicaid payers. She is a co-author on the post-marketing paper on dTMS for OCD published earlier this year.   \nScott Blackman\, CMBS \nScott Blackman has 30 years of medical device and pharmaceutical industry experience working in the areas of sales\, marketing\, and reimbursement.  Scott is currently the Director of Market Access for BrainsWay where he leads the reimbursement efforts for Deep transcranial magnetic stimulation (Deep TMS) technology.  Prior to BrainsWay\, Scott was the National Director for payer policy and reimbursement for Medical Technology Partners\, Inc. (MTP)\, a well-known and respected medical device reimbursement consulting company.  Scott played an important role at MTP by leading payer coverage acceleration and market access tactics and strategies for a number of medical device companies over the past nine years including neurostimulation technologies.  Before joining MTP\, he held market access and sales professional roles at Olympus\, Cyberonics (now known as LivaNova)\, and at his first healthcare company\, Pfizer.  During Scott’s 14-year career at Pfizer\, he promoted their CNS therapeutic products for conditions including depression\, obsessive-compulsive disorder\, bipolar disorder\, anxiety disorders\, schizophrenia\, and Alzheimer’s disease.  Thus\, he is very acquainted with the TMS industry and the challenges our customers face in the mental health market.  Before his healthcare career\, Scott served as a captain in the United States Marine Corps for nine years and is a graduate of the University of South Carolina. \nAron Tendler\, MD \nDr. Tendler is board certified in general psychiatry\, obesity medicine and sleep medicine. He sees patients thirty hours a week\, and is engaged in clinical research and education on neuromodulation as the Chief Medical Officer for BrainsWay thirty hours a week.
URL:https://clinicaltmssociety.org/event/how-to-best-utilize-the-new-ctmss-recommended-ocd-coverage-policy/
CATEGORIES:On-Demand Webinars
ATTACH;FMTTYPE=image/jpeg:https://clinicaltmssociety.org/wp-content/uploads/2024/11/2021_March_Insurance_Webinar_Thumbnail_V2.jpg
END:VEVENT
END:VCALENDAR